Curated News
By: NewsRamp Editorial Staff
March 10, 2026
Soligenix's Behçet's Disease Treatment Gets UK Promising Medicine Designation
TLDR
- Soligenix's SGX945 gains UK PIM designation, offering potential market advantage for treating Behçet's Disease with superior efficacy over existing options.
- The UK PIM designation for SGX945 is based on Phase 2 data showing favorable benefit-risk profile and potential inclusion in Early Access to Medicines Scheme.
- This designation accelerates access to promising treatment for Behçet's Disease patients, improving quality of life for those with rare inflammatory disorders.
- Soligenix's dusquetide represents a novel approach to treating Behçet's Disease, showcasing innovation in rare disease therapeutics through innate defense regulator technology.
Impact - Why it Matters
This development matters because Behçet's Disease is a rare, chronic inflammatory disorder that can cause painful mouth and genital sores, skin lesions, and potentially serious complications affecting the eyes, joints, and blood vessels. Current treatments are limited and often come with significant side effects. The PIM designation for SGX945 represents a critical step toward potentially providing patients with a new therapeutic option that clinical data suggests may offer advantages over existing treatments. For the rare disease community, regulatory pathways like the UK's Early Access to Medicines Scheme can significantly accelerate patient access to promising therapies, potentially improving quality of life and outcomes for those living with debilitating conditions. This advancement also demonstrates progress in addressing unmet medical needs in rare diseases, which often receive less research attention than more common conditions.
Summary
Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company, has achieved a significant regulatory milestone for its rare disease treatment pipeline. The company announced that its drug candidate SGX945 (dusquetide) received Promising Innovative Medicine ("PIM") designation from the U.K. Medicines and Healthcare Products Regulatory Agency for treating Behçet's Disease, a rare inflammatory disorder. This designation represents the crucial first step toward potential inclusion in the U.K.'s Early Access to Medicines Scheme, which could allow patients with life-threatening or seriously debilitating conditions to access promising therapies earlier than traditional approval pathways would permit. The PIM designation was granted based on Phase 2 clinical data suggesting that dusquetide may provide a significant advantage over existing treatments while demonstrating a favorable potential benefit-risk profile.
Beyond this specific development, Soligenix maintains a diverse portfolio addressing significant unmet medical needs across two business segments. Their Specialized BioTherapeutics segment includes HyBryte™ (SGX301) for cutaneous T-cell lymphoma, synthetic hypericin (SGX302) for psoriasis, and dusquetide (SGX942) for inflammatory diseases including oral mucositis in head and neck cancer. The company's Public Health Solutions segment focuses on vaccine development, incorporating their proprietary ThermoVax® heat stabilization platform technology for candidates targeting ricin toxin, filoviruses like Marburg and Ebola, and COVID-19 (CiVax™). These programs have received support from government agencies including the National Institute of Allergy and Infectious Diseases (NIAID), the Defense Threat Reduction Agency (DTRA), and the Biomedical Advanced Research and Development Authority (BARDA).
This news was distributed through BioMedWire ("BMW"), a specialized communications platform within the Dynamic Brand Portfolio @ IBN that focuses on biotechnology, biomedical sciences, and life sciences sectors. BioMedWire provides comprehensive distribution services including access to wire solutions via InvestorWire, article syndication to thousands of outlets, enhanced press release features, social media distribution through IBN's network, and tailored corporate communications solutions. For those interested in following developments from Soligenix, the company maintains a newsroom accessible through the provided link, and BioMedWire offers SMS alerts for biotech updates. This regulatory advancement for SGX945 represents not just progress for Soligenix but potential hope for patients suffering from Behçet's Disease who currently have limited treatment options.
Source Statement
This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Soligenix's Behçet's Disease Treatment Gets UK Promising Medicine Designation
